Opaleye Management Inc. purchased $30K of GRCE (indirect holdings)
Opaleye Management Inc. purchased 14,632 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at an average of $2.03 ($2.02–$2.04) across 3 trades over 2026-10-08 to 2026-10-12.
How this was made
The 30-second read
Why it matters
The filing provides a fresh data point on insider sentiment but the monetary amount is modest.
Market read
A small insider purchase adds slight positive sentiment but is unlikely to move the stock significantly.
What to watch
Potential upcoming clinical milestones for Grace Therapeutics that may have prompted the buy.
Background
Form 4 filings disclose insider transactions; Opaleye Management Inc. is a 10% owner of Grace Therapeutics and increased its holdings by 14,632 shares.
Ticker impact
SEC Form 4 shows Opaleye Management Inc. purchased ~30K of GRCE shares, increasing its stake to 2.87M shares.
likely slight upward pressure as the market prices the insider buy
The transaction size is modest (~$30K) and does not materially change ownership, but insider buying can be viewed positively.
Market effects
Minimal impact on the biotech sector; insider activity is routine.
None
None
Counterpoint
The purchase is too small to signal confidence; could be routine portfolio rebalancing.
Key entities
- CompanyGrace Therapeutics, Inc.
Biotech company whose shares were purchased by an insider.
- InsiderOpaleye Management Inc.
10% owner of Grace Therapeutics executing the purchase.
